Compass Pathways Eyes Rolling FDA Filing for COMP360, Preps TRD Launch Ahead of Q3 Data

Compass Pathways (NASDAQ:CMPS) executives outlined plans for a potential U.S. regulatory filing and commercial launch ...

Compass Pathways Highlights Phase 3 COMP360 TRD Gains, 26-Week Durability and FDA Path at Conference

Executives from Compass Pathways (NASDAQ:CMPS) discussed recent Phase 3 results for its COMP360 psilocybin program in ...
Seeking Alpha

Compass Pathways Successfully Achieves Primary Endpoint in First Phase 3 Trial Evaluating COMP360 Psilocybin for Treatment-Resistant Depression

LONDON & NEW YORK--(BUSINESS WIRE)-- Compass Pathways plc (CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation, announced today the successful ...
Seeking Alpha

Compass Pathways Announces First Quarter 2025 Financial Results and Business Highlights

LONDON & NEW YORK--(BUSINESS WIRE)-- Compass Pathways plc (CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, today reported its ...
Morningstar

Compass Pathways to Announce Third Quarter Financial Results on November 4, 2025

Compass Pathways plc (Nasdaq: CMPS) is a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health. We are motivated by the need to find better ways ...